{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:35:23Z","timestamp":1772278523269,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10157-025-02806-5","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:00:09Z","timestamp":1766062809000},"page":"480-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations"],"prefix":"10.1007","volume":"30","author":[{"given":"Nanaka","family":"Katsurayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-656X","authenticated-orcid":false,"given":"Hiroki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Unagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2806_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3949\/ccjm.85gr.18001","volume":"85","author":"J Augustine","year":"2018","unstructured":"Augustine J. Kidney transplant: new opportunities and challenges. Cleve Clin J Med. 2018;85:138\u201344.","journal-title":"Cleve Clin J Med"},{"key":"2806_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4293\/108680810X12924466007160","volume":"14","author":"GN Zografos","year":"2010","unstructured":"Zografos GN, Farfaras A, Vasiliadis G, Pappa T, Aggeli C, Vassilatou E, et al. Laparoscopic resection of large adrenal tumors. JSLS. 2010;14:364\u20138.","journal-title":"JSLS"},{"key":"2806_CR3","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.transproceed.2011.06.025","volume":"43","author":"C Ponticelli","year":"2011","unstructured":"Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation. Transplant Proc. 2011;43:2439\u201340.","journal-title":"Transplant Proc"},{"issue":"18","key":"2806_CR4","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.3390\/jcm12185938","volume":"12","author":"D Malhotra","year":"2023","unstructured":"Malhotra D, Jethwani P. Preventing rejection of the kidney transplant. J Clinic Med. 2023;12(18):5938.","journal-title":"J Clinic Med."},{"key":"2806_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/ckj\/sfx122","volume":"11","author":"B Sprangers","year":"2018","unstructured":"Sprangers B, Nair V, Launay-Vacher V, Riella LV, Jhaveri KD. Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J. 2018;11:315\u201329.","journal-title":"Clin Kidney J"},{"key":"2806_CR6","doi-asserted-by":"publisher","first-page":"15375","DOI":"10.18632\/oncotarget.23841","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Lan GB, Peng FH, Xie XB. Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies. Oncotarget. 2018;9:15375\u201385.","journal-title":"Oncotarget"},{"key":"2806_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/ckj\/sfv054","volume":"8","author":"G Stallone","year":"2015","unstructured":"Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J. 2015;8:637\u201344.","journal-title":"Clin Kidney J"},{"key":"2806_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"2806_CR9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116\u201327.","journal-title":"N Engl J Med"},{"key":"2806_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103\u201315.","journal-title":"N Engl J Med"},{"key":"2806_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829\u201341.","journal-title":"N Engl J Med"},{"key":"2806_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289\u2013300.","journal-title":"N Engl J Med"},{"key":"2806_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","volume":"100","author":"N Murakami","year":"2021","unstructured":"Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100:196\u2013205.","journal-title":"Kidney Int"},{"key":"2806_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf093","author":"H Ishihara","year":"2025","unstructured":"Ishihara H, Nishimura K, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, et al. Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. Jpn J Clin Oncol. 2025. https:\/\/doi.org\/10.1093\/jjco\/hyaf093.","journal-title":"Jpn J Clin Oncol"},{"key":"2806_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s10157-021-02038-3","volume":"25","author":"H Ishihara","year":"2021","unstructured":"Ishihara H, Fukuda H, Tachibana H, Yoshida K, Kobayashi H, Takagi T, et al. Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. Clin Exp Nephrol. 2021;25:674\u201382.","journal-title":"Clin Exp Nephrol"},{"key":"2806_CR16","doi-asserted-by":"publisher","first-page":"11960","DOI":"10.3389\/ti.2024.11960","volume":"37","author":"T Banno","year":"2024","unstructured":"Banno T, Hirai T, Oki R, Yagisawa T, Unagami K, Kanzawa T, et al. Higher donor age and severe microvascular inflammation are risk factors for chronic rejection after treatment of active antibody-mediated rejection. Transpl Int. 2024;37:11960.","journal-title":"Transpl Int"},{"issue":"2","key":"2806_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"Suppl 3","key":"2806_CR18","doi-asserted-by":"publisher","first-page":"iii 49","DOI":"10.1093\/annonc\/mdu259","volume":"25","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii 49-56.","journal-title":"Ann Oncol."},{"issue":"5","key":"2806_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2025.43.5_suppl.504","volume":"43","author":"J Wu","year":"2025","unstructured":"Wu J, Cui H-L, Shi H, Guan Y, Bi X-G, Zhou A, et al. Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma. J Clinic Oncol. 2025;43(5):504.","journal-title":"J Clinic Oncol."},{"key":"2806_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","volume":"65","author":"RR McKay","year":"2014","unstructured":"McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65:577\u201384.","journal-title":"Eur Urol"},{"key":"2806_CR21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ejca.2011.04.001","volume":"47","author":"A Kawashima","year":"2011","unstructured":"Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, et al. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Eur J Cancer. 2011;47:1521\u20136.","journal-title":"Eur J Cancer"},{"key":"2806_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/jjco\/hyy078","volume":"48","author":"H Ishihara","year":"2018","unstructured":"Ishihara H, Takagi T, Kondo T, Iwamoto K, Tachibana H, Yoshida K, et al. Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. Jpn J Clin Oncol. 2018;48:667\u201372.","journal-title":"Jpn J Clin Oncol"},{"key":"2806_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12032-018-1139-y","volume":"35","author":"K Iwamoto","year":"2018","unstructured":"Iwamoto K, Ishihara H, Takagi T, Kondo T, Yoshida K, Iizuka J, et al. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on\/1-week-off regimen for metastatic renal cell carcinoma. Med Oncol. 2018;35:78.","journal-title":"Med Oncol"},{"key":"2806_CR24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.kint.2016.11.008","volume":"91","author":"WH Lim","year":"2017","unstructured":"Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int. 2017;91:954\u201363.","journal-title":"Kidney Int"},{"key":"2806_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449\u201356.","journal-title":"Lancet"},{"key":"2806_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11273.x","volume":"110","author":"M Gigante","year":"2012","unstructured":"Gigante M, Neuzillet Y, Patard JJ, Tillou X, Thuret R, Branchereau J, et al. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int. 2012;110:E570-3.","journal-title":"BJU Int"},{"key":"2806_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","volume":"25","author":"V Kumar","year":"2020","unstructured":"Kumar V, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist. 2020;25:505\u201314.","journal-title":"Oncologist"},{"key":"2806_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","volume":"27","author":"L Spain","year":"2016","unstructured":"Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27:1135\u20137.","journal-title":"Ann Oncol"},{"key":"2806_CR29","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1470-2045(22)00395-3","volume":"23","author":"C Lebb\u00e9","year":"2022","unstructured":"Lebb\u00e9 C, Biard L, Delyon J, Zuber J. Managing immune checkpoint inhibition in transplant recipients. Lancet Oncol. 2022;23:969\u201371.","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02806-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:11:49Z","timestamp":1772266309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02806-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2806"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02806-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not receive any funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}